Last reviewed · How we verify
K-161
K-161 is a small molecule that targets the SGLT2 receptor.
K-161 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | K-161 |
|---|---|
| Sponsor | Kowa Research Institute, Inc. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, K-161 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly useful for the treatment of type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
- Increased risk of diabetic ketoacidosis
Key clinical trials
- A Study to Confirm the Efficacy and Safety of K-161 Ophthalmic Solution for Treatment of Moderate to Severe Dry Eye Disease (PHASE3)
- A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- K-161 CI brief — competitive landscape report
- K-161 updates RSS · CI watch RSS
- Kowa Research Institute, Inc. portfolio CI